Moderna, Inc. — Director's Dealing 2023

Jan 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-01-11

Reporting Person: AFEYAN NOUBAR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-11	Common Stock	S	10000	$188.57	Disposed	2257209	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12882819	Indirect
Common Stock	3924	Indirect

Footnotes

F1: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021, as amended on March 11, 2022.

F2: 10,801,059 shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and 2,081,760 shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F3: 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.